D.E. Shaw & Co
BIVV

D.E. Shaw & Co’s Bioverativ Inc. Common Stock BIVV Stock Holding History

D.E. Shaw & Co’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,927,374
Closed -$104M – 3948
2017
Q4 		$104M Buy
1,927,374
+226,535
+13% +$12.4M 0.14% 174
2017
Q3 		$97.1M Buy
1,700,839
+201,557
+13% +$11.8M 0.15% 163
2017
Q2 		$90.2M Buy
1,499,282
+801,692
+115% +$45.7M 0.15% 159
2017
Q1 		$38M Buy
+697,590
New +$34.4M 0.07% 352

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

D.E. Shaw & Co's BIVV Position: Q1 2018 in Review

D.E. Shaw & Co sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 1,927,374 shares — an estimated $104M sold.

D.E. Shaw & Co first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $104M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • D.E. Shaw & Co reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,927,374 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $104M.
  • D.E. Shaw & Co first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • D.E. Shaw & Co's Bioverativ Inc. Common Stock position peaked at $104M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on D.E. Shaw & Co's 13F filing for Q1 2018, filed 15 May 2018.